Table of Contents

| SUPPLEMENTAL METHODS | 2 |
|--|---|
| Model Implementation Details and SAS Programming Code2 | |
| Variable Details and Data Dictionary | 3 |
| Modified Poisson Regression with robust standard error | 4 |
| Analysis of Covariance (ANCOVA) with imputed values | 5 |
| Linear regression for censored data (tobit regression) | |
| Median regression for censored data | 7 |
| MMRM with imputed values | 8 |
| MMRM for censored data (LMEC) | |
| SUPPLEMENTAL TABLES AND FIGURES | 3 |
| Supplemental Table 1: Summary of Analysis Timepoints, Assay Limits, and Choice of Imputed Values for Quantitative SARS-CoV-2 RNA Below Assay Lower Limit of Quantification in Recent Outpatient COVID-19 Trials 13 | |
| Supplemental Table 2: Proportion with RNA <lloq 95%="" adjusting="" and="" baseline="" cis="" for="" p-values<br="" ratios,="" risk="" rna.="">among those with baseline viral RNA ≥LLoQ</lloq> | |
| Supplemental Figure 1: Consort Flow for Participants Included in Analysis | |
| REFERENCES 1 | 7 |

SUPPLEMENTAL METHODS

Model Implementation Details and SAS Programming Code

Below is a snapshot of the first 12 observations used in the illustrative example, with descriptive details on the variables used in

analysis. The following SAS programming code was used to implement each statistical model using SAS version 9.4.

| 0bs | PUBLICID | treatment | baserna | basernacat | visitday | rna | rnacat | changebase | lower | censor | rightchangebase |
|-----|----------|-----------|---------|------------|----------|------|---------|------------|-------|--------|-----------------|
| 1 | 50070162 | 1 | 6.50 | >= LLOQ | 3 | 2.68 | >= LL0Q | -3.82 | -3.82 | Θ | 103.82 |
| 2 | 50070162 | 1 | 6.50 | >= LLOQ | 7 | 2.00 | < LLOQ | -4.50 | | 1 | 104.50 |
| 3 | 50070162 | 1 | 6.50 | >= LLOQ | 14 | 2.00 | < LL0Q | -4.50 | | 1 | 104.50 |
| 4 | 50120111 | Θ | 2.00 | < LLOQ | 3 | 2.00 | < LLOQ | 0.00 | | 1 | 100.00 |
| 5 | 50120111 | Θ | 2.00 | < LLOQ | 7 | 2.00 | < LLOQ | 0.00 | | 1 | 100.00 |
| 6 | 50120111 | Θ | 2.00 | < LLOQ | 14 | 2.00 | < LLOQ | 0.00 | | 1 | 100.00 |
| 7 | 50140111 | 1 | 6.67 | >= LLOQ | 3 | | | | | | |
| 8 | 50140111 | 1 | 6.67 | >= LLOQ | 7 | 2.52 | >= LLOQ | -4.15 | -4.15 | 0 | 104.15 |
| 9 | 50140111 | 1 | 6.67 | >= LLOQ | 14 | 2.00 | < LLOQ | -4.67 | | 1 | 104.67 |
| 10 | 50140112 | Θ | 8.00 | >= LLOQ | 3 | 6.65 | >= LLOQ | -1.35 | -1.35 | 0 | 101.35 |
| 11 | 50140112 | Θ | 8.00 | >= LLOQ | 7 | 5.34 | >= LL0Q | -2.66 | -2.66 | 0 | 102.66 |
| 12 | 50140112 | Θ | 8.00 | >= LL00 | 14 | 2.00 | < LLOQ | -6.00 | | 1 | 106.00 |

Variable Details and Data Dictionary

| PUBLICID | Blinded participant ID variable for public dissemination |
|-----------------|---|
| TREATMENT | Treatment Indicator variable: 1 = tixagevimab/cilgavimab (active) and 0 = placebo |
| BASERNA | Baseline viral RNA (log ₁₀ copies/ml) |
| BASERNACAT | Categorical Baseline viral RNA: |
| BAGERNAGAT | '>= LLOQ' for quantifiable values and '< LLOQ' for values below the assay lower limit of quantification |
| VISITDAY | Post-Baseline Visit on day X, where X = 3, 7 or 14 days |
| RNA | Viral RNA (log ₁₀ copies/ml) on day X (defined by visitday). |
| | Results < LLoQ are imputed as 2 log_{10} copies/ml (which was the LLoQ) |
| RNACAT | Categorical viral RNA at on day X (defined by visitday): |
| | '>= LLOQ' for quantifiable values and '< LLOQ' for values below the assay lower limit of quantification |
| CHANGEBASE | Change in viral RNA (log ₁₀ copies/ml) from baseline to day X (defined by visitday): |
| ONANGEDAGE | Post-Baseline RNA on day X – Baseline RNA |
| LOWER | Analysis variable used in regression models for censored data. Lower = viral RNA value when the post- |
| | baseline value is quantifiable, and lower = "." (i.e., missing) when the post-baseline value is <lloq< td=""></lloq<> |
| CENSOR | Indicator variable whether the post-baseline value is left-censored (i.e., <lloq):< td=""></lloq):<> |
| | 1 = censored, 0 = not censored |
| RIGHTCHANGEBASE | Analysis variable used in quantile regression (as software is designed for right-censored data). |
| | changebase is transformed to a right-censored variable, calculated as: 100 – changebase |

Modified Poisson Regression with robust standard error

The proportion <LLoQ can be compared between arms adjusting for baseline viral RNA using a binary regression approach, such as modified Poisson regression with robust standard error [1] fit with generalized estimating equations (GEE) using an independence working correlation structure. We implement this model using PROC GENMOD with a Poisson distribution and log link function. The REPEATED statement is included to indicate that the viral RNA values are repeated in the dataset within person with ID number **publicid**, and TYPE=IND to use an independence working correlation structure.

PROC GENMOD DATA=dataset;

CLASS publicid treatment visitday;

MODEL censor = visitday treatment*visit baserna / DIST=POISSON LINK=LOG;

REPEATED SUBJECT=publicid / TYPE=IND;

Analysis of Covariance (ANCOVA) with imputed values

ANCOVA models can be implemented in SAS via several procedures. One such procedure is PROC GLM and can be implemented using the following code, including a where statement to restrict to those ≥LLoQ at baseline and to specify a post-baseline visit on Day X.

PROC GLM DATA=dataset;

WHERE **basernacat** = ">= LLOQ" and **visitday** = <insert>;

CLASS treatment;

MODEL changebase = treatment baserna / SOLUTION;

Linear regression for censored data (tobit regression)

Linear regression for censored data can be implemented in SAS using PROC LIFEREG, with restrictions in the where statement to subset to the population with baseline viral RNA \geq LLoQ and to a specific visit on Day X. The MODEL statement should reflect the left-censored nature of the viral RNA data, such that for each observation, the interval in the model (lower, upper) is the range of possible values the observation could take. For results \geq LLoQ, lower and upper values are identical and equal to the quantifiable viral RNA value. For results <LLoQ, the lower is set to missing (i.e., ".") and the upper is set to the change in viral RNA from baseline to the LLoQ of 2 log₁₀ copies/ml (i.e., 2 – baseline).

PROC LIFEREG DATA=dataset;

WHERE **basernacat** = ">= LLOQ" and **visitday** = <insert>;

CLASS treatment;

MODEL (lower, changebase) = treatment baserna / DISTRIBUTION=NORMAL;

Median regression for censored data

Quantile regression for survival data can be implemented in SAS using PROC QUANTLIFE (note that PROC QUANTREG is not appropriate in our setting as it requires all observations to be observed, so does not allow for censored measurements). To specify median regression, the 50th quantile should be indicated in the options of the MODEL statement. The outcome in the MODEL statement is composed of two pieces: the response variable and a variable indicating which observations are "censored" (note: here censored values are flagged as **censor=1**). Because this procedure has been designed to handle right-censored data, the response variable must be right censored in the analysis dataset. Therefore, we created an analysis variable called **rightchangebase** that is calculated as '100 – **changebase**' to ensure all values are right censored. Results need to be transformed back to the original scale of measurement for dissemination purposes.

PROC QUANTLIFE DATA=dataset;

```
WHERE basernacat = ">= LLOQ" and visitday = <insert>;
```

CLASS treatment;

MODEL rightchangebase*censor(1) = treatment baserna / QUANTILES=(0.50);

MMRM with imputed values

Mixed effects models for repeated measures can be implemented in SAS via PROC MIXED. Here, we use a REPEATED statement to indicate that we have repeated viral RNA values across study visits within SUBJECT labeled by **publicid**, and use an unstructured covariance structure (shown by TYPE=UN). The MODEL statement contains an interaction term between treatment and visit to calculate the treatment differences at each time point. Note: the WHERE statement only restricts the analysis to those ≥LLoQ at baseline as all post-baseline timepoints are included in the same model. If we wanted to restrict the post-baseline timepoints to include only Days 3 and 7 (as we did in our illustrative example) we would add an additional restriction here.

PROC MIXED DATA=dataset;

WHERE **basernacat** = ">= LLOQ";

CLASS publicid treatment visitday;

MODEL changebase = visitday treatment*visitday baserna / SOLUTION;

REPEATED visit / SUB=publicid TYPE=UN;

MMRM for censored data (LMEC)

The programming for the linear mixed effects model for censored data (LMEC) is more complex to implement as we wanted to create a repeated measures model with an unstructured covariance matrix. We opted to manually implement the likelihood function within PROC NLMIXED using the following programming code. Note: this code is specifically designed for two timepoints as it implements a bivariate normal distribution. The input dataset needs to be transposed so that for each time point (i.e., Day 3 and Day 7) there is a change in viral RNA and censor indicator for each person, and a new variable, **changes**, which is set to 2 if both Day 3 and Day 7 viral RNA are not missing, set to 1 if one viral RNA values is missing, and is set to missing if both Day 3 and Day 7 viral RNA are missing.

| 0bs | PUBLICID | treatment | baserna | basernacat | chg3 | rna3 | censor3 | chg7 | rna7 | censor7 | changes |
|-----|----------|-----------|---------|------------|-------|------|---------|-------|------|---------|---------|
| 1 | 50070162 | 1 | 6.50 | >= LL0Q | -3.82 | 2.68 | 0 | -4.50 | 2.00 | 1 | 2 |
| 2 | 50120111 | Θ | 2.00 | < LL00 | 0.00 | 2.00 | 1 | 0.00 | 2.00 | 1 | 2 |
| 3 | 50140111 | 1 | 6.67 | >= LL0Q | | | | -4.15 | 2.52 | Θ | 1 |
| 4 | 50140112 | Θ | 8.00 | >= LL0Q | -1.35 | 6.65 | Θ | -2.66 | 5.34 | Θ | 2 |
| 25 | 50760132 | 1 | 5.15 | >= LLOQ | | | | | | | |

PROC NLMIXED DATA=dataset_transpose;

WHERE **basernacat** = ">= LLOQ";

PARMS alpha3=3 alpha7=3 trt3=1 trt7=1 bsl3=3 bsl7=3 rho=0 sd3=1 sd7=1;

BOUNDS 1 > rho > -1, sd3 sd7 > 0;

pi = CONSTANT('pi');

mu3 = alpha3 + bsl3*baserna + trt3*treatment;

mu7 = alpha7 + bsl7*baserna + trt7*treatment;

z3 = (**chg3**-mu3)/sd3;

z7 = (**chg7**-mu7)/sd7;

rhosq=rho*rho;

IF ((chg3 NE .) AND (chg7 NE .)) THEN DO;

IF (censor3=0 AND censor7=0) THEN

 $L = -\log(2^{*}pi) - \log(sd3) - \log(sd7) - (0.5^{*}\log(1-rhosq)) - ((z3^{**}2 - (2^{*}rho^{*}z3^{*}z7) + z7^{**}2) / (2^{*}(1-rhosq)));$

ELSE IF (censor3=0 AND censor7=1) THEN

L = -0.5*log(2*pi) - log(sd3) - (z3*z3/2) + log(PROBNORM((chg7 - (mu7 + (rho*sd7*z3))) / (sd7*sqrt(1-rhosq))));

ELSE IF (censor3=1 AND censor7=0) THEN

L = -0.5*log(2*pi) - log(sd7) - (z7*z7/2) + log(PROBNORM((chg3 - (mu3 + (rho*sd3*z7))) / (sd3*sqrt(1-rhosq))));

ELSE IF (censor3=1 AND censor7=1) THEN

L = PROBBNRM(z3, z7, rho);

END;

ELSE IF((chg3 NE .) AND (chg7 EQ .)) THEN DO;

IF (censor3 = 0) THEN L = $-0.5*(\log(2*pi)) - \log(sd3) - (z3*z3/2);$

ELSE IF (censor3 = 1) THEN L = log(PROBNORM(z3));

END;

ELSE IF ((chg3 EQ .) AND (chg7 NE .)) THEN DO;

IF (censor7 = 0) THEN L = -0.5*(log(2*pi)) - log(sd7) - (z7*z7/2);

ELSE IF (censor7 = 1) THENL = log(PROBNORM(z7));

END;

```
ELSE IF ((chg3 EQ .) AND (chg7 EQ .)) THEN DO;
```

L = .;

END;

MODEL changes ~ GENERAL(L);

SUPPLEMENTAL TABLES AND FIGURES

Supplemental Table 1: Summary of Analysis Timepoints, Assay Limits, and Choice of Imputed Values for Quantitative SARS-CoV-2 RNA Below Assay Lower Limit of Quantification in Recent Outpatient COVID-19 Trials

| Study | Analysis Timepoints (Days) | Assay Limits | Imputation Method |
|------------------|-------------------------------|---|--|
| ACTIV-2 [2] | 0ª, 3, 7, 14 ^b | LLoQ: 2 log ₁₀ copies/ml | BLoQ and detectable \rightarrow midpoint of LLoQ and LOD |
| | | LOD: 1.4 log ₁₀ copies/ml | BLoQ and undetectable \rightarrow midpoint of LOD and zero |
| REGEN-COV and | 1ª, 7, 15, 29 | LLoQ: 2.85 log10 copies/ml | BLoQ and detectable \rightarrow midpoint of LLoQ and zero |
| REGEN-COV2 [3,4] | 1ª, 3, 5, 7 | | BLoQ and undetectable \rightarrow 0 log ₁₀ copies/ml |
| BLAZE-1 and | 1ª, 3, 5, 7, 11 | Ct limit: 45 | Negative \rightarrow equal to the Ct limit (0 log ₁₀ copies/ml) |
| BLAZE-4 [5–7] | | | |
| Molnupiravir [8] | 1ª, 3, 5, 7, 14 | LLoQ 3 log ₁₀ copies/ml | $BLoQ \rightarrow equal to the LLoQ$ |
| TACKLE [9] | 1ª, 3, 6, 15, 29 | LLoQ: 3.348 log ₁₀ copies/ml | $BLoQ \rightarrow midpoint of LLoQ and zero$ |
| COMET-ICE [10] | 1ª, 8 | LLoQ: 3.35 log10 copies/ml | BLoQ and detectable \rightarrow midpoint of LLoQ and LOD |
| | | LOD: 3.17 log10 copies/ml | BLoQ and undetectable \rightarrow midpoint of LOD and zero |
| Peginterferon | 0ª, 7, 10, 14 | Ct limit: 40 (i.e., LOD: 1.6 | $BLoD \rightarrow Ct = 42$ (i.e., 1 log ₁₀ copies/ml) |
| Lambda-1a [11] | | log ₁₀ copies/ml) | |
| CONV-ERT [12] | 0ª, 7, 28 | LOD: 3 log ₁₀ copies/ml | $BLoD \rightarrow equal to the limit$ |
| TOGETHER [13] | 0ª, 3, 7 or 0ª,1-14 | LOD: 1 log ₁₀ copies/ml | $BLoD \rightarrow 0 \log_{10} \text{ copies/ml}$ |

| STOIC [14] | 0ª, 7, 14 | Ct limit: 40 | $BLoD \rightarrow equal to the Ct limit$ |
|--------------------|------------------------|--|--|
| Hydroxychloroquine | 1ª, 3, 7 | LOD 3 log ₁₀ copies/ml | $BLoD \rightarrow equal to the LOD$ |
| [15] | | | |
| EPIC-HR [16] | 1ª, 3, 5, 10, 14 | LOD: 2 log ₁₀ copies/ml | $BLoD \rightarrow midpoint of LOD and zero$ |
| MOVE-OUT [17] | 1ª, 3, 5, 10, 15, 29 | LLoQ: 2.70 log ₁₀ copies/ml | $BLoQ \rightarrow 1$ copy lower than LLoQ |
| Remdesivir [18] | 0ª, 2, 3, 7 | LLoQ: 3.35 log10 copies/ml | BLoQ and detectable \rightarrow midpoint of LLoQ and zero |
| | | LOD: 3.17 log10 copies/ml | BLoQ and undetectable \rightarrow midpoint of LOD and zero |
| Ensitrelvir [19] | 1ª, 2, 4, 6, 9, 14, 21 | LLoQ: 2.08 log10 copies/ml | $BLoQ \rightarrow equal to the limit$ |

^aBaseline Timepoint; ^bDays 21 and 28 dropped from later protocol versions. BLoQ = Below Limit of Quantification; LLoQ = Lower Limit of Quantification; LOD = Limit of Detection; BLOD = Below Limit of Detection; Ct = Cycle Threshold. Studies identified through PubMed search and review of COVID treatment guidelines.

Supplemental Table 2: Proportion with RNA <LLoQ adjusting for Baseline RNA. Risk Ratios, 95% CIs and p-values among

those with baseline viral RNA ≥LLoQ


| Global P-value ^a | Day 3 | Day 7 | Day 14 | | | | | | |
|--|--|----------------------------|--------|--|--|--|--|--|--|
| G: GEE Model (Modified Poisson Regression) across all three days | | | | | | | | | |
| 0.86 | 0.86 1.00 (0.47, 2.13) 1.20 (0.81, 1.77) 1.08 (0.87, 1.33) p=0.99 p=0.36 p=0.50 | | | | | | | | |
| H: GEE Model (Modified Poisson Regression) across Days 3 and 7 | | | | | | | | | |
| 0.71 | 1.02 (0.51, 2.03) p=0.96 | 1.20 (0.79 1.82) p=0.40 | | | | | | | |

^aGlobal p-value based on Wald's test. Risk ratios obtained using Modified Poisson Regression with robust standard error, fit with

generalized estimating equations and independence working correlation. This model is not restricted to those >LLoQ at baseline.

GEE = Generalized Estimating Equation; N/A = Not Applicable.

Supplemental Figure 1: Consort Flow for Participants Included in Analysis



NP = Nasopharyngeal; LLoQ = Lower Limit of Quantification

REFERENCES

- 1. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004; 159(7):702–706.
- 2. Chew KW, Moser C, Daar ES, et al. Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19. Nat Commun. Nature Publishing Group; **2022**; 13(1):4931.
- 3. Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. N Engl J Med. Massachusetts Medical Society; **2021**; 385(23):e81.
- 4. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. Massachusetts Medical Society; **2021**; 384(3):238–251.
- 5. Dougan M, Azizad M, Mocherla B, et al. A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load. Clin Infect Dis Off Publ Infect Dis Soc Am. **2021**; :ciab912.
- 6. Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. N Engl J Med. Massachusetts Medical Society; **2021**; 385(15):1382–1392.
- Dougan M, Azizad M, Chen P, et al. Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19 [Internet]. medRxiv; 2022 [cited 2023 Feb 9]. p. 2022.03.10.22272100. Available from: https://www.medrxiv.org/content/10.1101/2022.03.10.22272100v1
- Fischer WA, Eron JJ, Holman W, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. American Association for the Advancement of Science; 2021; 14(628):eabl7430.
- Montgomery H, Hobbs FDR, Padilla F, et al. Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. Elsevier; 2022; 10(10):985–996.
- 10. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. **2022**; 327(13):1236–1246.
- 11. Jagannathan P, Andrews JR, Bonilla H, et al. Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. Nat Commun. Nature Publishing Group; **2021**; 12(1):1967.

- Alemany A, Millat-Martinez P, Corbacho-Monné M, et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respir Med. Elsevier; 2022; 10(3):278– 288.
- 13. Reis G, Moreira Silva EAS, Medeiros Silva DC, et al. Early Treatment with Pegylated Interferon Lambda for Covid-19. N Engl J Med. Massachusetts Medical Society; **2023**; 388(6):518–528.
- 14. Ramakrishnan S, Nicolau DV, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. Elsevier; **2021**; 9(7):763–772.
- 15. Mitjà O, Corbacho-Monné M, Ubals M, et al. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial. Clin Infect Dis Off Publ Infect Dis Soc Am. **2020**; :ciaa1009.
- 16. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. Massachusetts Medical Society; **2022**; 386(15):1397–1408.
- 17. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. Massachusetts Medical Society; **2022**; 386(6):509–520.
- Gottlieb RL, Vaca CE, Paredes R, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med. Massachusetts Medical Society; 2022; 386(4):305–315.
- Mukae H, Yotsuyanagi H, Ohmagari N, et al. Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19): The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study. Clin Infect Dis. 2022; ciac933.